Merck's Vasotec in NHLBI studies
Executive Summary
Two randomized, controlled trials are being sponsored by the National Heart, Lung & Blood Institute to determine the effectiveness of enalapril in improving survival of patients with left ventricular dysfunction. Effects of the ACE inhibitor on quality of life, biventricular functions, arrhythmias, exercise tolerance, neurohormonal changes and major morbidity will also be assessed. Studies, which are being conducted at 23 centers in the U.S., Canada and Belgium, will enroll 4,500 asymptomatic congestive heart failure patients to the prevention trial and 2,600 symptomatic patients to the treatment trial.